The 24-year study of more than 1.2 million children in Denmark found that aluminum exposure didn't raise the risk of autism, asthma, or other chronic diseases. Other science and research news is on ...

AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial, indicating that the highly selective aldosterone synthase inhibitor (ASI), baxdrostat, significantly lowered the mean seated ...

Shadow Business Secretary Andrew Griffith calls on chancellor Rachel Reeves to rule out tax rises on wealth creators ahead of ...